Emergent Biosolutions
EBS
255 hedge funds and large institutions have $1.72B invested in Emergent Biosolutions in 2022 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 78 increasing their positions, 95 reducing their positions, and 43 closing their positions.
85% more call options, than puts
Call options by funds: $4.92M | Put options by funds: $2.67M
12% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 43
3.28% more ownership
Funds ownership: 79.49% → 82.77% (+3.3%)
0% more funds holding
Funds holding: 254 → 255 (+1)
5% less capital invested
Capital invested by funds: $1.81B → $1.72B (-$96.4M)
18% less repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 95
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$28.9M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$22.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$19.3M |
| 4 |
Renaissance Technologies
New York
|
+$15.8M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$45.4M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$35.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$31.6M |
| 4 |
SCM
Snyder Capital Management
San Francisco,
California
|
-$21.1M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$18.1M |
EBS Hedge Fund Activity: Q1 2022 in Review
255 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2022, worth a combined $1.72B — down 5.3% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new EBS positions and 43 closed out — a net gain of 5 holders — while 78 added to existing stakes and 95 trimmed.
The largest buyer was BlackRock, adding an estimated $28.9M. The largest seller was Janus Henderson Group, cutting an estimated $45.4M.
- 255 institutional investors held Emergent Biosolutions (EBS) as of Q1 2022, up from 254 in Q4 2021.
- Funds reported $1.72B of Emergent Biosolutions stock for Q1 2022, down 5.3% quarter-over-quarter.
- 48 funds opened new Emergent Biosolutions positions in Q1 2022 and 43 closed out, a net change of +5 holders.
- The largest Emergent Biosolutions buyer in Q1 2022 was BlackRock, an estimated $28.9M added.
- The largest Emergent Biosolutions seller in Q1 2022 was Janus Henderson Group, an estimated $45.4M sold.
Based on aggregated 13F filings for Q1 2022.